RB1 loss (inclusive of LOF mutations and deep deletions) was seen at similar frequencies in both ERBB2amp and ERBB2mut bladder cancer (21.2% and 25.1%, respectively) and NSCLC (9.7% and 10.5%, respectively) and less frequently in other tumor types. This evidence concerns the gene RB1 and neoplasm.